证券日报网讯九安医疗（002432）9月9日在互动平台回答投资者提问时表示，公司的薪酬体系从开展第 一次股票期权激励计划开始，就已经转变为现金+股权的薪酬包模式，期权激励计划和持股计划均是公 司员工薪酬体系的一部分，公司在现金部分的标准相较于同行业、同规模的公司属于较低的，股权部分 是为了更好的实现股东、公司和员工三方的利益绑定。请投资者理解，公司希望通过员工参与的股权部 分让员工体会到其工作的投入对公司价值的影响，提升员工的工作积极性，这会直接给公司经营基本面 带来价值。高管取得的股权激励情况，公司已在激励方案中进行了披露。 ...

Group 1 - The company, Jiann Medical, responded to investor inquiries on September 9 regarding its historical cash dividend situation, indicating that investors should pay attention to the company's equity distribution implementation announcement [2]

Core Viewpoint - The company is enhancing its brand recognition and market presence in the home respiratory virus screening sector through the development of single-test reagent kits and plans to expand its product offerings in the IVD field [1] Group 1 - The company has established strong brand awareness by launching single-test reagent kits, which has effectively opened up the market [1] - Following the introduction of the triple-test product, the company aims to continuously expand the range of detectable virus sequences [1] - The company is committed to ongoing research and development efforts to diversify its OTC/POC in vitro diagnostic products [1]

Core Viewpoint - The company is optimistic about the market prospects for diabetes-related products, given the increasing global prevalence of diabetes and the relatively low competition in the market [1] Industry Summary - Diabetes is one of the most prevalent chronic diseases globally, with the number of affected individuals reaching 529 million in 2021 and projected to rise to 1.31 billion by 2050, indicating a significant market opportunity [1] - The company is actively advancing its "Internet + Healthcare" strategy, focusing on the new "O+O" model for diabetes care, which has been implemented in approximately 50 cities across China and 424 hospitals, managing over 366,000 diabetes patients [1] - In the United States, the company has partnered with around 74 clinics and 394 doctors, providing care to approximately 21,000 patients, with substantial growth in patient numbers and related revenue in recent years [1] - The U.S. healthcare system has begun reimbursing for internet healthcare services, and similar policies are gradually being established in China [1]

Core Viewpoint - The company, Jiuan Medical (002432), is focused on asset preservation and appreciation, leveraging a professional asset management team to enhance its investment strategies [1] Group 1: Asset Management Strategy - The company has established a dedicated asset management team with experienced professionals in the field [1] - Jiuan Medical is actively engaging in large asset allocation business primarily through its wholly-owned subsidiary, Jiuan Hong Kong [1] Group 2: Financial Performance - The fair value changes and investment income generated from the investment business are classified as recurring gains [1] - The large asset allocation business is expected to significantly boost the company's net profit attributable to shareholders in the first half of 2025, with an anticipated increase of 52.91% compared to the same period last year [1]

Group 1 - The company has completed multiple batches of pilot production for continuous glucose monitoring (CGM) devices and is actively conducting clinical-related work domestically [1] - The company is also advancing the research and development of CGM products for international markets [1] - The CGM product will be integrated into a new "O+O" model for diabetes diagnosis and care, which is expected to accelerate the implementation and development of the company's core strategy [1] Group 2 - The company aims to create a high-frequency, sticky customer base through effective service in the "O+O" model, which can generate good synergy effects [1]

（文章来源：每日经济新闻） 九安医疗（002432.SZ）9月9日在投资者互动平台表示，截至目前公司已完成首期10.5亿元中期票据的 发行工作，年化利率为1.83%，本次债券的成功发行，拓宽了公司融资渠道，优化了负债结构和财务成 本。首期中期票据的募集资金用途为偿还有息负债、科技创新领域的研发支出和补充流动资金，公司将 根据实际用途情况，严格按照银行间市场交易商协会的相关监管要求，统筹安排本次募集资金的使用。 每经AI快讯，有投资者在投资者互动平台提问：请问科技创新债中期票据目前工作进展到什么阶段？ ...

2025年9月8日，九安医疗(002432.SZ)在互动平台上回答表示，在持续血糖监测（CGM）领域，公司已 完成多批次试生产，目前已在国内积极开展型检和临床相关工作，同时也在积极推进国外CGM产品的 研发工作。该产品未来在市场销售的同时，还将被整合应用于糖尿病诊疗照护"O+O"新模式中，可加速 推动公司该核心战略的实施和发展，且通过有效深耕并深度服务于"O+O"新模式形成的高频粘性客户， 可形成较好的协同效应。 ...

Group 1 - The company has completed multiple batches of trial production for Continuous Glucose Monitoring (CGM) devices and is actively conducting domestic testing and clinical work [2] - The company is also advancing the research and development of CGM products for international markets [2] - The CGM product will be integrated into a new "Online + Offline" (O+O) model for diabetes care, which is expected to accelerate the implementation of the company's core strategy and development [2] Group 2 - The company aims to create a high-frequency, sticky customer base through effective engagement and deep service in the O+O model, which could lead to good synergy effects [2]

Group 1 - The company has invested in a fund called TianKai JiuAn HaiHe HaiTang Sci-Tech Mother Fund with a total investment of 5 billion RMB, contributing up to 3.56 billion RMB or equivalent in USD [2] - The fund has invested 100 million RMB in MuXi Technology, and the company's shareholding in MuXi is minimal, indicating it will not significantly impact the company's operational performance [2] - The company's management discussion and analysis in the 2025 semi-annual report includes information on collaboration with professional investors for joint investments and direct investment activities [2]